Sylvie Negrier


Ontology type: schema:Person     


Person Info

NAME

Sylvie

SURNAME

Negrier

Publications in SciGraph latest 50 shown

  • 2018-12 Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses in BMC CANCER
  • 2018-12 Activity of cabozantinib in radioresistant brain metastases from renal cell carcinoma: two case reports in JOURNAL OF MEDICAL CASE REPORTS
  • 2018-05 The tyrosine-kinase inhibitor sunitinib targets vascular endothelial (VE)-cadherin: a marker of response to antitumoural treatment in metastatic renal cell carcinoma in BRITISH JOURNAL OF CANCER
  • 2017-12 Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors in BMC CANCER
  • 2017-09-26 CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas in BRITISH JOURNAL OF CANCER
  • 2016-05 First-Line Treatments for Poor-Prognosis Metastatic Renal Cell Carcinoma: Experts’ Prescribing Practices and Systematic Literature Review in CLINICAL DRUG INVESTIGATION
  • 2016-02 Determination of unbound fraction of pazopanib in vitro and in cancer patients reveals albumin as the main binding site in INVESTIGATIONAL NEW DRUGS
  • 2015-10 A serum metabolomic fingerprint of bevacizumab and temsirolimus combination as first-line treatment of metastatic renal cell carcinoma in BRITISH JOURNAL OF CANCER
  • 2014-06 Pharmacokinetics of pazopanib administered in combination with bevacizumab in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2014 Antiangiogenic Drugs in Cancer Therapy: Effect on Advanced Renal Cell Carcinoma in MOLECULAR MECHANISMS OF ANGIOGENESIS
  • 2014-01 Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2013-03 Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib in BRITISH JOURNAL OF CANCER
  • 2013 Treatment of Metastatic Kidney Cancer in the Elderly in MANAGEMENT OF UROLOGICAL CANCERS IN OLDER PEOPLE
  • 2012-08 Antiangiogenic treatments and mechanisms of action in renal cell carcinoma in INVESTIGATIONAL NEW DRUGS
  • 2012-05 Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α in BRITISH JOURNAL OF CANCER
  • 2012-03 Acceleration of clear cell renal cell carcinoma growth in mice following bevacizumab/Avastin treatment: the role of CXCL cytokines in ONCOGENE
  • 2011-07 Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies in BRITISH JOURNAL OF CANCER
  • 2010-10 A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer in BRITISH JOURNAL OF CANCER
  • 2010-09 Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET in MEDICAL ONCOLOGY
  • 2010 Comparison of Artificial Neural Network with Logistic Regression as Classification Models for Variable Selection for Prediction of Breast Cancer Patient Outcomes in ADVANCES IN ARTIFICIAL NEURAL SYSTEMS
  • 2008-12 O-Mel-Inib: A Cancéro-pôle Nord-Ouest multicenter phase II trial of high-dose Imatinib mesylate in metastatic uveal melanoma in INVESTIGATIONAL NEW DRUGS
  • 2008-11 Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2007-04 Bulletin de synthèse de veille 2006 in ONCOLOGIE
  • 2006-04 Nonmetastatic renal-cell carcinoma: is it really possible to define rational guidelines for post-treatment follow-up? in NATURE REVIEWS CLINICAL ONCOLOGY
  • 2005-07 Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d’Immunothérapie in WORLD JOURNAL OF UROLOGY
  • 2005-06 Treatment of Liver Metastases From Uveal Melanoma in ANNALS OF SURGICAL ONCOLOGY
  • 2004-03 Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma in BRITISH JOURNAL OF CANCER
  • 2003-08 Summary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site (2002) in BRITISH JOURNAL OF CANCER
  • 2001 Cutaneous melanoma in BRITISH JOURNAL OF CANCER
  • 1998-01 Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 1997-01 Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma in BRITISH JOURNAL OF CANCER
  • 1995 Adoptive Immunotherapy with Interleukin-2 and LAK Cells or Gene Modified TIL in Patients with Renal Cell Carcinoma: Clinical and Laboratory Data in BIOLOGY OF RENAL CELL CARCINOMA
  • 1994-12 Corrigendum in BRITISH JOURNAL OF CANCER
  • 1994-06 Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma in BRITISH JOURNAL OF CANCER
  • 1994-01 Pretreatment serum CRP and response to interleukin 2 in BRITISH JOURNAL OF CANCER
  • 1994 Interleukin-2 Therapy: Report on 129 Patients and Three Different Schedules in CONTEMPORARY RESEARCH ON RENAL CELL CARCINOMA
  • 1994 Clinical application of gene transfer in oncology: preliminary results of a French study in CANCER TREATMENT AN UPDATE
  • 1993-11 Patients with metastatic renal carcinoma candidate for immunotherapy with cytokines. Analysis of a single institution study on 181 patients in BRITISH JOURNAL OF CANCER
  • 1993-07 Phase II study of fotemustine as second-line treatment after failure of immunotherapy in metastatic renal cell carcinoma in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 1993 Interleukin-2 and lymphokine activated killer (LAK) cells in THE ROLE OF INTERLEUKIN-2 IN THE TREATMENT OF CANCER PATIENTS
  • 1992-10 Kidney in INTENSIVE CARE MEDICINE
  • 1992-05 Intravenous interleukin-2 in patients over 65 with metastatic renal carcinoma in BRITISH JOURNAL OF CANCER
  • 1991-08 Acute renal failure with preserved renal plasma flow induced by cancer immunotherapy in KIDNEY INTERNATIONAL
  • 1991 Immunotherapy in metastatic renal cell cancer. The Lyon’s experience on 100 patients in PROCEEDINGS OF THE 3RD INTERNATIONAL CONGRESS ON NEO-ADJUVANT CHEMOTHERAPY
  • 1990 Adoptive Immunotherapy with IL-2 in 27 Patients with Metastatic Renal Cell Carcinoma in CYTOKINES IN HEMOPOIESIS, ONCOLOGY, AND AIDS
  • 1990 Stimulation of the Immune System for the Therapy of Advanced Stage Neuroblastoma in EXPERIMENTAL HEMATOLOGY TODAY—1989
  • 1990 Interleukin-2 (IL-2) After Autologous Bone Marrow Transplantation (BMT):A Pilot Study of Late Administration, 2–3 Months Post ABMT in CYTOKINES IN HEMOPOIESIS, ONCOLOGY, AND AIDS
  • 1990 rIL-2 Immunotherapy for 19 Children with Advanced Metastatic Neuroblastoma in CYTOKINES IN HEMOPOIESIS, ONCOLOGY, AND AIDS
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "affiliation": [
          {
            "affiliation": {
              "id": "https://www.grid.ac/institutes/grid.418116.b", 
              "type": "Organization"
            }, 
            "isCurrent": true, 
            "type": "OrganizationRole"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.10419.3d", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.170205.1", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.414303.1", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.418191.4", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.411142.3", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.6582.9", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.476460.7", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.417829.1", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.1052.6", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.5252.0", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.412220.7", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.150338.c", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.239578.2", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.9851.5", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.410569.f", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.416351.4", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.42399.35", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.412730.3", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.443984.6", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.412753.6", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.410513.2", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.414339.8", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.25697.3f", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.420044.6", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.417570.0", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.239395.7", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.414093.b", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.240372.0", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.7849.2", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.38142.3c", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.5645.2", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.14925.3b", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.424926.f", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.51462.34", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.5802.f", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.412530.1", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.418443.e", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.412180.e", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.7700.0", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.411095.8", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.50956.3f", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.470869.4", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.418596.7", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.48769.34", 
            "type": "Organization"
          }
        ], 
        "familyName": "Negrier", 
        "givenName": "Sylvie", 
        "id": "sg:person.0723756046.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0723756046.31"
        ], 
        "sdDataset": "persons", 
        "sdDatePublished": "2019-03-07T14:57", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-uberresearch-data-dimensions-researchers-20181010/20181011/dim_researchers/base/researchers_660.json", 
        "type": "Person"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/person.0723756046.31'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/person.0723756046.31'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/person.0723756046.31'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/person.0723756046.31'


     

    This table displays all metadata directly associated to this object as RDF triples.

    104 TRIPLES      10 PREDICATES      55 URIs      7 LITERALS      2 BLANK NODES

    Subject Predicate Object
    1 sg:person.0723756046.31 schema:affiliation N868b49ca9f3441f0bbd4a56df9b9f879
    2 https://www.grid.ac/institutes/grid.10419.3d
    3 https://www.grid.ac/institutes/grid.1052.6
    4 https://www.grid.ac/institutes/grid.14925.3b
    5 https://www.grid.ac/institutes/grid.150338.c
    6 https://www.grid.ac/institutes/grid.170205.1
    7 https://www.grid.ac/institutes/grid.239395.7
    8 https://www.grid.ac/institutes/grid.239578.2
    9 https://www.grid.ac/institutes/grid.240372.0
    10 https://www.grid.ac/institutes/grid.25697.3f
    11 https://www.grid.ac/institutes/grid.38142.3c
    12 https://www.grid.ac/institutes/grid.410513.2
    13 https://www.grid.ac/institutes/grid.410569.f
    14 https://www.grid.ac/institutes/grid.411095.8
    15 https://www.grid.ac/institutes/grid.411142.3
    16 https://www.grid.ac/institutes/grid.412180.e
    17 https://www.grid.ac/institutes/grid.412220.7
    18 https://www.grid.ac/institutes/grid.412530.1
    19 https://www.grid.ac/institutes/grid.412730.3
    20 https://www.grid.ac/institutes/grid.412753.6
    21 https://www.grid.ac/institutes/grid.414093.b
    22 https://www.grid.ac/institutes/grid.414303.1
    23 https://www.grid.ac/institutes/grid.414339.8
    24 https://www.grid.ac/institutes/grid.416351.4
    25 https://www.grid.ac/institutes/grid.417570.0
    26 https://www.grid.ac/institutes/grid.417829.1
    27 https://www.grid.ac/institutes/grid.418191.4
    28 https://www.grid.ac/institutes/grid.418443.e
    29 https://www.grid.ac/institutes/grid.418596.7
    30 https://www.grid.ac/institutes/grid.420044.6
    31 https://www.grid.ac/institutes/grid.42399.35
    32 https://www.grid.ac/institutes/grid.424926.f
    33 https://www.grid.ac/institutes/grid.443984.6
    34 https://www.grid.ac/institutes/grid.470869.4
    35 https://www.grid.ac/institutes/grid.476460.7
    36 https://www.grid.ac/institutes/grid.48769.34
    37 https://www.grid.ac/institutes/grid.50956.3f
    38 https://www.grid.ac/institutes/grid.51462.34
    39 https://www.grid.ac/institutes/grid.5252.0
    40 https://www.grid.ac/institutes/grid.5645.2
    41 https://www.grid.ac/institutes/grid.5802.f
    42 https://www.grid.ac/institutes/grid.6582.9
    43 https://www.grid.ac/institutes/grid.7700.0
    44 https://www.grid.ac/institutes/grid.7849.2
    45 https://www.grid.ac/institutes/grid.9851.5
    46 schema:familyName Negrier
    47 schema:givenName Sylvie
    48 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0723756046.31
    49 schema:sdDatePublished 2019-03-07T14:57
    50 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    51 schema:sdPublisher N56d67c7c92e94dd9851ce727f81bf05e
    52 sgo:license sg:explorer/license/
    53 sgo:sdDataset persons
    54 rdf:type schema:Person
    55 N56d67c7c92e94dd9851ce727f81bf05e schema:name Springer Nature - SN SciGraph project
    56 rdf:type schema:Organization
    57 N868b49ca9f3441f0bbd4a56df9b9f879 schema:affiliation https://www.grid.ac/institutes/grid.418116.b
    58 sgo:isCurrent true
    59 rdf:type schema:OrganizationRole
    60 https://www.grid.ac/institutes/grid.10419.3d schema:Organization
    61 https://www.grid.ac/institutes/grid.1052.6 schema:Organization
    62 https://www.grid.ac/institutes/grid.14925.3b schema:Organization
    63 https://www.grid.ac/institutes/grid.150338.c schema:Organization
    64 https://www.grid.ac/institutes/grid.170205.1 schema:Organization
    65 https://www.grid.ac/institutes/grid.239395.7 schema:Organization
    66 https://www.grid.ac/institutes/grid.239578.2 schema:Organization
    67 https://www.grid.ac/institutes/grid.240372.0 schema:Organization
    68 https://www.grid.ac/institutes/grid.25697.3f schema:Organization
    69 https://www.grid.ac/institutes/grid.38142.3c schema:Organization
    70 https://www.grid.ac/institutes/grid.410513.2 schema:Organization
    71 https://www.grid.ac/institutes/grid.410569.f schema:Organization
    72 https://www.grid.ac/institutes/grid.411095.8 schema:Organization
    73 https://www.grid.ac/institutes/grid.411142.3 schema:Organization
    74 https://www.grid.ac/institutes/grid.412180.e schema:Organization
    75 https://www.grid.ac/institutes/grid.412220.7 schema:Organization
    76 https://www.grid.ac/institutes/grid.412530.1 schema:Organization
    77 https://www.grid.ac/institutes/grid.412730.3 schema:Organization
    78 https://www.grid.ac/institutes/grid.412753.6 schema:Organization
    79 https://www.grid.ac/institutes/grid.414093.b schema:Organization
    80 https://www.grid.ac/institutes/grid.414303.1 schema:Organization
    81 https://www.grid.ac/institutes/grid.414339.8 schema:Organization
    82 https://www.grid.ac/institutes/grid.416351.4 schema:Organization
    83 https://www.grid.ac/institutes/grid.417570.0 schema:Organization
    84 https://www.grid.ac/institutes/grid.417829.1 schema:Organization
    85 https://www.grid.ac/institutes/grid.418116.b schema:Organization
    86 https://www.grid.ac/institutes/grid.418191.4 schema:Organization
    87 https://www.grid.ac/institutes/grid.418443.e schema:Organization
    88 https://www.grid.ac/institutes/grid.418596.7 schema:Organization
    89 https://www.grid.ac/institutes/grid.420044.6 schema:Organization
    90 https://www.grid.ac/institutes/grid.42399.35 schema:Organization
    91 https://www.grid.ac/institutes/grid.424926.f schema:Organization
    92 https://www.grid.ac/institutes/grid.443984.6 schema:Organization
    93 https://www.grid.ac/institutes/grid.470869.4 schema:Organization
    94 https://www.grid.ac/institutes/grid.476460.7 schema:Organization
    95 https://www.grid.ac/institutes/grid.48769.34 schema:Organization
    96 https://www.grid.ac/institutes/grid.50956.3f schema:Organization
    97 https://www.grid.ac/institutes/grid.51462.34 schema:Organization
    98 https://www.grid.ac/institutes/grid.5252.0 schema:Organization
    99 https://www.grid.ac/institutes/grid.5645.2 schema:Organization
    100 https://www.grid.ac/institutes/grid.5802.f schema:Organization
    101 https://www.grid.ac/institutes/grid.6582.9 schema:Organization
    102 https://www.grid.ac/institutes/grid.7700.0 schema:Organization
    103 https://www.grid.ac/institutes/grid.7849.2 schema:Organization
    104 https://www.grid.ac/institutes/grid.9851.5 schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...